Tam CS, et al. - Experts evaluated the effectiveness of daily oral ibrutinib and venetoclax in patients with relapsed or refractory mantle-cell lymphoma or previously untreated mantle-cell lymphoma. The age of the subjects was 47 to 81 years and the number of previous treatments ranged from none to 6. Ibrutinib monotherapy was given at a dose of 560 mg per day. After 4 weeks, venetoclax was added in stepwise, weekly increasing doses to 400 mg per day. Data displayed that the complete response rate according to computed tomography at week 16 was 42%, which was higher compared to the historical result of 9% at this time point with ibrutinib monotherapy. It was determined that dual targeting of BTK and BCL2 with ibrutinib and venetoclax was consistent with improved outcomes in patients with mantle-cell lymphoma were predicted to present with poor outcomes with current therapy.